Pharmaceutical company GSK has announced its $1 billion upfront purchase of Aiolos Bio, an asthma-focused drug developer. The deal includes up to an additional $400 million in payments if certain milestones are met. Aiolos, based in San Francisco and London, was just launched last year and announced a $245 million Series A round in October. The company is preparing for a Phase 2 trial of its candidate AIO-001 in adult asthma. This acquisition is part of a series of pharma acquisitions that are generating optimism for the industry’s prospects in the year ahead.
Source link
GSK to buy asthma-focused Aiolos Bio in $1 billion deal
